Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al.
Friesen I, Saluzzo F, Groenheit R, Aubry A, Anthony R, Niemann S, Mathys V, Cirillo DM; TB European Reference Laboratory Network (ERLTB-Net-3); Indra A, Mathys V, Atanasova Y, Obrovac M, Žmak L, Pieridou D, Dvořáková V, Lillebæk T, Kummik T, Klaos K, Soini H, Haanperä-Heikkinen M, Mentula S, Jérôme R, Cambau E, Niemann S, Panayotis I, Papaventsis D, Bakos Á, Szél V, Lőrinczi LK, Fitzgibbon M, Boyle B, Cirillo DM, Giannoni F, Pole I, Norvaiša I, Vasiliauskaite L, Perrin M, Deguara C, Anthony R, Mengshoel AT, Augustynowicz-Kopeć E, Macedo R, Coriu RM, Porvaznik I, Klemen Š, Herrera-León L, Groenheit R, Werngren J.
Friesen I, et al. Among authors: anthony r.
Clin Microbiol Infect. 2024 Jun 6:S1198-743X(24)00277-5. doi: 10.1016/j.cmi.2024.06.001. Online ahead of print.
Clin Microbiol Infect. 2024.
PMID: 38851424
No abstract available.